Liberate Generics!

Generic competition to accelerate the number of people who start treatment is stalled due to Gilead’s, AbbVie’s, and their sub-licensees’ delay or failure to register their drugs. More

Gilead’s license is a fool’s bargain that inhibits access for nearly half the world’s HCV population. More

This is the first time in Europe that a medical NGO uses this juridical tool to improve patients access to treatment. More

Compulsory license ends Gilead’s dangerous games with lives of hepatitis C patients in Malaysia; Result of hard fought efforts of community-based groups, NGOs and treatment providers. More

Advocates scandalized that Gilead’s hepatitis C profits have raked in US$25.8 billion, which could have treated everyone while still earning US$16 billion in profits. More

Activists’ demonstrations demanding affordable hepatitis C treatment and universal access to generic medicines everywhere. More

New treatment combination for hepatitis C virus is an additional affordable option for millions still waiting for access to lifesaving treatments in middle-income countries. More

Gilead claims there is a patent infringement by two generic producers and directly asked to block any eventual commercialization of sofosbuvir products by these producers in Brazil. More

Sofosbuvir case in Brazil is well analysed in a new publication ’Access to Medicines and Vaccines: Implementing Flexibilities Under Intellectual Property Law’. More

Four years after MPP and AbbVie came to agreement on a voluntary license authorizing MPP to sublicense G/P to generic manufacturers, generic G/P is not available anywhere. More